Opana® ER (oxymorphone) – Request for market removal
June 8, 2017 – The FDA requested that Endo remove Opana ER (oxymorphone hyrdochloride) extended-release tablets from the market as the FDA has concluded that the benefits of the drug may no longer outweigh its risks.
Download PDF
